Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Abbott launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for average-risk adults 45+, developed by Freenome and commercialized by Abbott. The test showed 81.1% CRC sensitivity and 90.4% specificity; it is covered by Medicare.Material DetailsContext by AI Analys…
ABBOTT PARK, Ill., Sept. 30, 2026 // -- Abbott (NYSE:ABT) today announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer (CRC) screening test for adults age 45 and older who are at average risk for the disease. Developed and manufactured by…